Published financial brief
3791B
VTV THERAPEUTICS INC
- As of
- 2024-12-31
- Source
- Supabase fundamentals
- Calculator
- financial-roic-1.0.0
- Published
- 7/26/2026
4 data notes
- Input provenance requires review.
- A ratio denominator is near zero.
- One or more values are unavailable.
- A displayed ratio exceeds the warning bound.
Exact-period record
Fundamentals
5 reported periods
| Metric | FY 20202020-12-31 | FY 20212021-12-31 | FY 20222022-12-31 | FY 20232023-12-31 | FY 20242024-12-31 |
|---|---|---|---|---|---|
| Financial statements | |||||
| RevenueUSD millions | 6.4 | 4 | 2 | 0 | 1 |
| Cost of goods soldUSD millions | 18.2 | 24 | 24.5 | 25.4 | 25.1 |
| Selling, general and administrative expenseUSD millions | —missing | —missing | —missing | —missing | —missing |
| Depreciation and amortizationUSD millions | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Net incomeUSD millions | -8.5 | -13 | -19.2 | -20.3 | -18.5 |
| Operating profit (EBIT)USD millions | -11.9 | -20.1 | -22.5 | -25.5 | -24.2 |
| Income taxesUSD millions | 0 | 0.1 | 0.2 | 0 | 0.1 |
| Short-term debtUSD millions | 0.2 | 0.4 | 0.4 | 0.4 | 0.2 |
| Long-term debtUSD millions | 0.7 | 0.5 | 0.3 | 0.2 | 0 |
| Cash and equivalentsUSD millions | 5.7 | 13.4 | 12.1 | 9.4 | 36.7 |
| ReceivablesUSD millions | 0.2 | 0.1 | 12.4 | 0.1 | 0.1 |
| InventoryUSD millions | 0 | 0 | 0 | 0 | 0 |
| PayablesUSD millions | 1.9 | 1.9 | 2.5 | 4.1 | 0.9 |
| Net property, plant and equipmentUSD millions | 0.8 | 0.7 | 0.6 | 0.4 | 0.2 |
| Capital expenditureUSD millions | 0 | 0 | 0 | 0 | 0 |
| Operating cash flowUSD millions | -18 | -19.3 | -16 | -19.1 | -25.3 |
| Prepaid expensesUSD millions | 0.9 | 1.9 | 2.5 | 1 | 1.2 |
| AccrualsUSD millions | 4.2 | 6.1 | 4.9 | 6.2 | 4.1 |
| EBITDAUSD millions | -11.8 | -20 | -22.4 | -25.4 | -24.1 |
| Working capitalUSD millions | 0.8 | 7.1 | 19.4 | 0 | 32.9 |
| Working capital requirementUSD millions | -1.8 | -1.8 | 10 | -4 | -0.9 |
| Total debtUSD millions | 0.9 | 0.9 | 0.7 | 0.5 | 0.2 |
| Free cash flowUSD millions | -18 | -19.3 | -16 | -19.1 | -25.3 |
| Unlevered free cash flowUSD millions | -12.2 | -19.9 | -34.2 | -11.5 | -27.2 |
| Returns and ratios | |||||
| ROICratio | 1,291.1% | 1,761.4% | -214.4% | 706% | 3,339.8% |
| Pre-tax ROICratio | 1,291.1% | 1,761.4% | -214.4% | 706% | 3,339.8% |
| Effective tax rateratio | 0% | 0% | 0% | 0% | 0% |
| Revenue growthratio | 132.1% | -37.6% | -49.6% | -100% | —missing |
| EBIT / Revenueratio | -184.8% | -500.9% | -1,116.9% | —missing | -2,377.6% |
| Revenue / Invested capitalmultiple | -6.99× | -3.52× | 0.19× | 0× | -1.4× |
| Cogs Over Revenuesratio | 283.3% | 598.7% | 1,212.4% | —missing | 2,468.8% |
| Sga Over Revenuesratio | —missing | —missing | —missing | —missing | —missing |
| Da Over Revenuesratio | 1.5% | 2.2% | 4.6% | —missing | 8.8% |
| Nfa Over Revenuesratio | 13.2% | 17% | 27.6% | —missing | 15% |
| Wcr Over Revenuesratio | -27.5% | -45.4% | 493.3% | —missing | -86.2% |
| Debt Over Ebitdamultiple | —missing | —missing | —missing | —missing | —missing |
| St Debt Over Cashmultiple | 0.04× | 0.03× | 0.03× | 0.04× | 0× |
| Interest Over Ebitdamultiple | —missing | —missing | —missing | —missing | —missing |
| Interest Over Nocf Nicfmultiple | -0.04× | -0× | -0× | -0× | 0× |
| Nsf Over Wcrmultiple | 3.12× | 7.13× | -1.18× | 2.29× | 41.71× |
Ask this snapshot
Research assistant
3791B · annualSnapshot fe27f5d4
Answers use only this published snapshot. The assistant will say when the data is insufficient and does not create forecasts, scenarios, or investment advice.
0 / 2,000